[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"invasive-mycosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:invasive-mycosis":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100340829",false,"NCT03717623","Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants","Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection","POPULAR","Inclusion Criteria:\n\n* Adult (≥18 years old) haematology patients receiving Posaconazole prophylaxis in the inpatient setting as standard of care.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Unable to give informed consent.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.",[26,27,28,29,30,31,32],"Posaconazole","Pharmacokinetics","Invasive Candidiases","Invasive Aspergillosis","Invasive Mycosis","Fungal Infection","Prophylaxis","RECRUITING","2025-02-26",{"date":36,"type":37},"2025-02-28","ACTUAL",{"date":39,"type":37},"2019-08-01",{"date":41,"type":20},"2025-12-30",{"name":43,"class":44},"Melbourne Health","OTHER",""]